Expression of T-cell Immunoglobulin- and Mucin-domain-containing Molecule 3 (TIM-3)and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease with anti TNF-α Therapy
研究概览
简要总结
This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's disease during anti TNF-α (infliximab) therapy.
详细描述
The immunoregulatory effects of TIM-3 on patients with Crohn's disease according to the treatment have not yet been investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 13 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- ••Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment
- •confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings
排除标准
- ••patients who has proven to have infliximab antibody
研究组 & 干预措施
TIM-3
T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity.
干预措施: Infliximab (Drug)
结局指标
主要结局
Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease with anti TNF-α Therapy
时间窗: 1-year treatment period
Disease Activity Index (PCDAI) scores, Peripheral blood for TIM-3 mRNA expression
次要结局
未报告次要终点
研究者
YonHo Choe
Pediatrics
Samsung Medical Center